Henney Kilowatt

Global and China Automotive Vision Industry Research Report 2023 Featuring 20 Chinese Vision Enterprises, 17 Foreign Vision Enterprises, and Summary and Trends of Visual Enterprises - ResearchAndMarkets.com

Retrieved on: 
Monday, March 11, 2024
Vehicle Technology, Other Automotive, Other Technology, Technology, Automotive, Autonomy, BYD, Model Y, Original equipment manufacturer, DJI, Volkswagen, Tier 1, Great Wall Motor, Lotus, ADAS, Sale, Software, ADS, Geely, Huawei, Dongfeng, Henney Kilowatt, Mercedes-Benz C-Class, Safety, BYD Han, Dynasty, SAIC, Camera

The "Automotive Vision Industry Research Report, 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Automotive Vision Industry Research Report, 2023" report has been added to ResearchAndMarkets.com's offering.
  • It was estimated that the total installation of cameras will hit 65.065 million units in 2023, a figure projected to jump to 93.022 million in 2026.
  • From January to September 2023, new cars in China were installed with 8.946 million front view mono cameras, up 34.5% from the prior-year period.
  • OEMs have begun to treat intelligent driving rationally, and automakers tend to adopt "in-house R&D + outsourcing" parallel intelligent driving R&D strategies.

PepsiCo Celebrates Next Generation of HBCU Musicians and Student Changemakers with $160,000 Donation from Doritos® SOLID BLACK

Retrieved on: 
Thursday, August 24, 2023
Partnership, Journal of Multilingual and Multicultural Development, DJ, Student, Pepsi Zero Sugar, Culture, Donation, Historically black colleges and universities, Henney Kilowatt, Backstreet Boys: Larger Than Life, SOLID, PepsiCo, Black, Creativity, Doritos, School, Global Changemakers, Collection, Brick, Next Generation, SVP, Empowerment, Social media, Tourism, Television, Nightclub, HBCU, University

PURCHASE, N.Y., Aug. 24, 2023 /PRNewswire/ -- PepsiCo is proudly making its return to the 2023 Pepsi National Battle of the Bands to celebrate, elevate, and engage students and the nation's top Historically Black Colleges and Universities (HBCUs) marching bands, recognizing how deeply rooted these institutions are in HBCU culture and their fundamental role in shaping the HBCU experience.

Key Points: 
  • A portion of the funds will be going to support students individually as Doritos SOLID BLACK continues to spotlight Black Changemakers who are creating meaningful impact.
  • "As a fellow HBCU alum and previous Doritos SOLID BLACK Changemaker, I'm thrilled to welcome these new honorary changemakers.
  • Ahead of the drop date, eight kits including the entire collection will be given to the Doritos SOLID BLACK band changemakers.
  • Doritos SOLID BLACK has recognized and amplified more than 25 Black Changemakers in partnership with the PepsiCo Foundation.

OncoHost Collaborates with BGN Technologies to Predict Cancer Patient Response to Anti-PD-1 Treatment with IcAR Biosensing Tech

Retrieved on: 
Thursday, May 4, 2023
Faculty, ICIS, Partnership, Drug development, ICI, Ligand, Cancer, Henney Kilowatt, Biomarker, Immunotherapy, Oncology, Patient, Physician, Medicine, PD-L2, BGU, Diagnosis, Ben-Gurion University of the Negev, PD-1, PD-L1, Palladium, Pharmaceutical industry, Medical imaging

BEER-SHEVA, Israel and BINYAMINA, Israel, May 4, 2023 /PRNewswire/ -- OncoHost, a technology company transforming the approach to precision medicine for improved patient outcomes, today announced that it has signed an option agreement with BGN Technologies, the technology transfer company of Ben-Gurion University of the Negev (BGU), to receive a license for a novel biosensing technology called IcAR (Immuno-checkpoint Artificial Reporter). IcAR was developed by a team of researchers from BGU.

Key Points: 
  • With only 20-40% of cancer patients responding to immune checkpoint inhibitor (ICI) treatment, better biomarkers are desperately needed.
  • The IcAR biosensing technology measures the binding functionality of PD-1 ligands, PD-L1 and PD-L2, to their receptor, PD-1.
  • "IcAR technology is expected to be a game-changer in the world of cancer treatment diagnostics," said Prof. Elkabets.
  • In the future, this bioassay technology may help predict response to additional ICI therapies and could be used to tailor personalized treatment protocols.

Senti Bio Highlights Preclinical Data from Multiple Gene Circuit Enabled Cell Therapy Programs at Annual AACR Meeting

Retrieved on: 
Monday, April 17, 2023
SNTI, HSPC, AACR, Survival, Bone marrow, American Association for Cancer Research, NK, Doctor of Philosophy, Health, MDS, CAR, AML, Science, Investigational New Drug, CD33, Patient, Logic, FLT3, EMCN, IND, Henney Kilowatt, HCC, Pharmaceutical industry, Vaccine, Silk, Fine chemical, Mobile phone, MD

SOUTH SAN FRANCISCO, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary gene circuit platform, today announced the presentation of preclinical data from multiple wholly-owned pipeline programs at the American Association for Cancer Research (AACR) Annual Meeting being held April 14-19, 2023, in Orlando, Florida. Senti Bio is advancing a pipeline of gene circuit-enabled chimeric antigen receptor natural killer (CAR-NK) cell therapies for the treatment of liquid and solid tumors.

Key Points: 
  • Senti Bio is advancing a pipeline of gene circuit-enabled chimeric antigen receptor natural killer (CAR-NK) cell therapies for the treatment of liquid and solid tumors.
  • “We are excited to share strong preclinical data on SENTI-202 as the program advances towards the clinic,” said Tim Lu, MD, PhD, Chief Executive Officer and Co-Founder of Senti Bio.
  • The posters are also available on the Scientific Presentations & Publications page on the Senti Bio website.
  • These data demonstrate that NK cells engineered to co-express CAR and crIL-15 can improve persistence and anti-tumor activity of CAR-NK cells.